SCYNEXIS, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-12-31 was 0.00 shares.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-06-30 was 166.00 shares.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-03-31 was 0.00 shares.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 166.00 shares, a 99.26% decline from fiscal 2019.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 22.50K shares.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2018 was 0.00 shares.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | 166.00 shares 10-K · filed 2021-03-29 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | 166.00 shares derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-06-30 | 166.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 22.67K shares derived: sum of 4 quarters · filed 2020-08-10 |
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-11 | 22.50K shares derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | 22.50K shares 10-K · filed 2020-03-11 |
| 2019-09-30 | 22.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 22.50K shares derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 0.00 shares derived: sum of 4 quarters · filed 2019-08-07 |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-08 | 0.00 shares derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | 0.00 shares 10-K · filed 2019-03-14 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | 0.00 shares derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 0.00 shares derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-08 | 0.00 shares derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | 0.00 shares 10-K · filed 2019-03-14 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | |
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-08 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2017-03-13 | |
| 2015-12-31 | 0.00 shares 10-K · filed 2017-03-13 | |
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-07 | 416.00 shares 10-K · filed 2016-03-07 |
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | |
| 2014-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2014-08-13 | |
| 2014-03-31 | 416.00 shares 10-Q/A · filed 2014-07-11 | |
| 2013-12-31 | 220.00 shares 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |